• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    10 Health Care Stocks With Whale Alerts In Today's Session

    3/28/24 1:35:26 PM ET
    $ABBV
    $AKBA
    $AVDL
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABBV alert in real time by email

    This whale alert can help traders discover the next big trading opportunities.

    Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

    Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels.

    Here's the list of options activity happening in today's session:

    Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume
    AKBA PUT SWEEP BEARISH 04/19/24 $2.00 $31.2K 6.5K 4.4K
    BMY CALL TRADE NEUTRAL 06/21/24 $60.00 $26.0K 6.2K 559
    EHC CALL SWEEP BEARISH 04/19/24 $80.00 $48.0K 1.1K 554
    UNH CALL SWEEP BEARISH 04/05/24 $500.00 $142.2K 1.4K 490
    NVO PUT SWEEP BEARISH 06/21/24 $160.00 $31.0K 523 250
    VRTX CALL TRADE BEARISH 04/26/24 $450.00 $36.5K 0 159
    ABBV CALL TRADE NEUTRAL 05/17/24 $175.00 $52.4K 1.2K 89
    AVDL PUT SWEEP BEARISH 01/17/25 $20.00 $27.0K 185 82
    DHR PUT SWEEP BEARISH 01/17/25 $260.00 $178.5K 92 79
    MRNA CALL TRADE BEARISH 01/17/25 $125.00 $35.7K 1.4K 31

    Explanation

    These itemized elaborations have been created using the accompanying table.

    • For AKBA (NASDAQ:AKBA), we notice a put option sweep that happens to be bearish, expiring in 22 day(s) on April 19, 2024. This event was a transfer of 1060 contract(s) at a $2.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $31.2K, with a price of $30.0 per contract. There were 6593 open contracts at this strike prior to today, and today 4467 contract(s) were bought and sold.

    • Regarding BMY (NYSE:BMY), we observe a call option trade with neutral sentiment. It expires in 85 day(s) on June 21, 2024. Parties traded 500 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $26.0K, with a price of $52.0 per contract. There were 6277 open contracts at this strike prior to today, and today 559 contract(s) were bought and sold.

    • For EHC (NYSE:EHC), we notice a call option sweep that happens to be bearish, expiring in 22 day(s) on April 19, 2024. This event was a transfer of 160 contract(s) at a $80.00 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $48.0K, with a price of $300.0 per contract. There were 1185 open contracts at this strike prior to today, and today 554 contract(s) were bought and sold.

    • Regarding UNH (NYSE:UNH), we observe a call option sweep with bearish sentiment. It expires in 8 day(s) on April 5, 2024. Parties traded 400 contract(s) at a $500.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $142.2K, with a price of $355.0 per contract. There were 1496 open contracts at this strike prior to today, and today 490 contract(s) were bought and sold.

    • For NVO (NYSE:NVO), we notice a put option sweep that happens to be bearish, expiring in 85 day(s) on June 21, 2024. This event was a transfer of 10 contract(s) at a $160.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $31.0K, with a price of $3104.0 per contract. There were 523 open contracts at this strike prior to today, and today 250 contract(s) were bought and sold.

    • For VRTX (NASDAQ:VRTX), we notice a call option trade that happens to be bearish, expiring in 29 day(s) on April 26, 2024. This event was a transfer of 159 contract(s) at a $450.00 strike. The total cost received by the writing party (or parties) was $36.5K, with a price of $230.0 per contract. There were 0 open contracts at this strike prior to today, and today 159 contract(s) were bought and sold.

    • Regarding ABBV (NYSE:ABBV), we observe a call option trade with neutral sentiment. It expires in 50 day(s) on May 17, 2024. Parties traded 57 contract(s) at a $175.00 strike. The total cost received by the writing party (or parties) was $52.4K, with a price of $920.0 per contract. There were 1273 open contracts at this strike prior to today, and today 89 contract(s) were bought and sold.

    • Regarding AVDL (NASDAQ:AVDL), we observe a put option sweep with bearish sentiment. It expires in 295 day(s) on January 17, 2025. Parties traded 52 contract(s) at a $20.00 strike. This particular put needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $27.0K, with a price of $520.0 per contract. There were 185 open contracts at this strike prior to today, and today 82 contract(s) were bought and sold.

    • For DHR (NYSE:DHR), we notice a put option sweep that happens to be bearish, expiring in 295 day(s) on January 17, 2025. This event was a transfer of 79 contract(s) at a $260.00 strike. This particular put needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $178.5K, with a price of $2260.0 per contract. There were 92 open contracts at this strike prior to today, and today 79 contract(s) were bought and sold.

    • For MRNA (NASDAQ:MRNA), we notice a call option trade that happens to be bearish, expiring in 295 day(s) on January 17, 2025. This event was a transfer of 24 contract(s) at a $125.00 strike. The total cost received by the writing party (or parties) was $35.7K, with a price of $1490.0 per contract. There were 1436 open contracts at this strike prior to today, and today 31 contract(s) were bought and sold.

    Options Alert Terminology
    - Call Contracts: The right to buy shares as indicated in the contract.
    - Put Contracts: The right to sell shares as indicated in the contract.
    - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it.
    - Premium/Option Price: The price of the contract.

    For more information, visit our Guide to Understanding Options Alerts or read more about unusual options activity.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABBV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABBV
    $AKBA
    $AVDL
    $BMY

    CompanyDatePrice TargetRatingAnalyst
    Vertex Pharmaceuticals Incorporated
    $VRTX
    3/10/2026$580.00Buy
    Jefferies
    Novo Nordisk A/S
    $NVO
    3/10/2026$42.00Buy → Hold
    TD Cowen
    Vertex Pharmaceuticals Incorporated
    $VRTX
    3/10/2026$540.00 → $600.00Outperform
    Oppenheimer
    Novo Nordisk A/S
    $NVO
    3/3/2026$40.00Underweight → Equal-Weight
    Morgan Stanley
    Novo Nordisk A/S
    $NVO
    3/2/2026$41.00Buy → Neutral
    Goldman
    Bristol-Myers Squibb Company
    $BMY
    2/25/2026$60.00Sector Perform
    RBC Capital Mkts
    AbbVie Inc.
    $ABBV
    2/25/2026$260.00Outperform
    RBC Capital Mkts
    Novo Nordisk A/S
    $NVO
    2/24/2026Buy → Hold
    Kepler
    More analyst ratings

    $ABBV
    $AKBA
    $AVDL
    $BMY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and President Butler John P. bought $86,588 worth of shares (69,270 units at $1.25), increasing direct ownership by 2% to 3,367,064 units (SEC Form 4)

    4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

    3/5/26 6:55:46 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & President Kewalramani Reshma bought $3,895,768 worth of shares (10,000 units at $389.58), increasing direct ownership by 9% to 115,968 units (SEC Form 4)

    4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

    8/7/25 4:23:31 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sachs Bruce I bought $1,948,416 worth of shares (5,000 units at $389.68), increasing direct ownership by 12% to 45,000 units (SEC Form 4)

    4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

    8/7/25 4:19:03 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AKBA
    $AVDL
    $BMY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Sr. Vice Pres. and Treasurer Fay Edmund gifted 3,000 units of Encompass Health Common Stock and sold $1,277,259 worth of Encompass Health Common Stock (11,937 units at $107.00), decreasing direct ownership by 15% to 86,325 units (SEC Form 4)

    4 - Encompass Health Corp (0000785161) (Issuer)

    3/10/26 1:43:57 PM ET
    $EHC
    Hospital/Nursing Management
    Health Care

    SVP, Controller Purdue David Ryan sold $1,221,519 worth of shares (5,230 units at $233.56), decreasing direct ownership by 66% to 2,654 units (SEC Form 4)

    4 - AbbVie Inc. (0001551152) (Issuer)

    3/6/26 5:05:44 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, CHIEF HR OFFICER Crum Demetris D covered exercise/tax liability with 1,594 shares, decreasing direct ownership by 17% to 7,914 units (SEC Form 4)

    4 - AbbVie Inc. (0001551152) (Issuer)

    3/6/26 5:02:27 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AKBA
    $AVDL
    $BMY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy

    - For the primary endpoint, patients treated with povetacicept achieved a 52.0% reduction from baseline in proteinuria as measured by 24-hour urine protein to creatinine ratio (UPCR) and achieved a statistically significant and clinically meaningful 49.8% reduction in UPCR versus placebo (P<0.0001) – - For the first secondary endpoint, povetacicept treatment led to a 77.4% reduction from baseline in serum Gd-IgA1, resulting in a statistically significant and clinically meaningful reduction of 79.3% (P<0.0001) versus placebo; for the second secondary endpoint, 85.1% of povetacicept-treated patients achieved hematuria resolution, resulting in a statistically significant and clinically meani

    3/9/26 4:02:00 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

    ABBV-295 treatment showed clinically meaningful body weight reduction from -7.75% to -9.79% (least-squares mean) at week 12 (weekly dosing), to -7.86% to -9.73% at week 13 (every other week and monthly dosing after week 5)1ABBV-295 demonstrated a favorable tolerability profile at all evaluated dose levels.  No serious adverse events were reported1Data support continued development of ABBV-295 as a potentially differentiated treatment for chronic weight management, with a non-incretin-based mechanism of action NORTH CHICAGO, Ill., March 9, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced positive topline results1 from the multiple ascending dose (MAD) part of its Phase 1 study evaluati

    3/9/26 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma

    Study marks the first positive Phase 3 study for mezigdomide and the second positive Phase 3 study for the Bristol Myers Squibb CELMoD program Bristol Myers Squibb (NYSE:BMY) today announced positive interim Phase 3 results from the SUCCESSOR-2 study (NCT05552976). In the trial, oral mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus carfilzomib and dexamethasone alone (Kd) in patients with relapsed or refractory multiple myeloma (RRMM). Safety findings were consistent with the known profile of mezigdomide and the combination regimen. Patients will con

    3/9/26 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AKBA
    $AVDL
    $BMY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    January 30, 2025 - FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain

    For Immediate Release: January 30, 2025 Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals reach the brain.  Journavx is the first dr

    1/30/25 5:46:14 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    10/18/24 4:38:13 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form

    10/17/24 1:29:31 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AKBA
    $AVDL
    $BMY
    SEC Filings

    View All

    SEC Form 8-K filed by Encompass Health Corporation

    8-K - Encompass Health Corp (0000785161) (Filer)

    3/10/26 4:49:25 PM ET
    $EHC
    Hospital/Nursing Management
    Health Care

    UnitedHealth Group Incorporated filed SEC Form 8-K: Regulation FD Disclosure

    8-K - UNITEDHEALTH GROUP INC (0000731766) (Filer)

    3/9/26 4:33:13 PM ET
    $UNH
    Medical Specialities
    Health Care

    SEC Form PRE 14A filed by AbbVie Inc.

    PRE 14A - AbbVie Inc. (0001551152) (Filer)

    3/9/26 4:31:02 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AKBA
    $AVDL
    $BMY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Vertex Pharma with a new price target

    Jefferies initiated coverage of Vertex Pharma with a rating of Buy and set a new price target of $580.00

    3/10/26 8:43:03 AM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novo Nordisk A/S downgraded by TD Cowen with a new price target

    TD Cowen downgraded Novo Nordisk A/S from Buy to Hold and set a new price target of $42.00

    3/10/26 8:39:23 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer reiterated coverage on Vertex Pharma with a new price target

    Oppenheimer reiterated coverage of Vertex Pharma with a rating of Outperform and set a new price target of $600.00 from $540.00 previously

    3/10/26 8:19:07 AM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AKBA
    $AVDL
    $BMY
    Leadership Updates

    Live Leadership Updates

    View All

    Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

    WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Dr. Nader brings more than 30 years of leadership experience across the biotechnology and pharmaceutical industry and currently serves as an Independent Director of Moderna, Inc. (NASDAQ:MRNA), a glo

    2/23/26 4:01:00 PM ET
    $MRNA
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Danaher To Acquire Masimo Corporation

    WASHINGTON, Feb. 17, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ:MASI) a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care settings. Under the terms of the agreement, Danaher will acquire all of the outstanding shares of Masimo common stock for $180 per share in cash, or a total enterprise value of approximately $9.9 billion including assumed indebtedness and net of acquired cash. This represents a transaction multiple of approximately 18x estimated 2027 EBITDA, or 15x 2

    2/17/26 8:00:00 AM ET
    $DHR
    $MASI
    Industrial Machinery/Components
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Encompass Health appoints Cain Hayes to its board of directors

    BIRMINGHAM, Ala., Feb. 2, 2026 /PRNewswire/ -- Encompass Health Corp. (NYSE:EHC) today announced the appointment of Cain A. Hayes to its board of directors. Hayes joins the Encompass Health board with significant experience in health care, strategic leadership, human capital management, risk management and governmental regulation. He retired as president and chief executive officer of Point32Health, Inc., a top-20 U.S. health plan, in 2024. Prior to joining Point32Health in 2021, he served as president and chief executive officer of Gateway Health Plan, Inc., following a long

    2/2/26 8:00:00 AM ET
    $EHC
    Hospital/Nursing Management
    Health Care

    $ABBV
    $AKBA
    $AVDL
    $BMY
    Financials

    Live finance-specific insights

    View All

    Bristol Myers Squibb Announces Dividend

    Bristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the company. The dividend is payable on May 1, 2026, to stockholders of record at the close of business on April 2, 2026. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol Myers Squibb, our mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for the future of medicine and the patients we serve. For more information about Bristol Myers Squibb, visit u

    3/2/26 4:16:00 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights

    Q4 2025 net product revenues of $54.3 million; 2025 full-year net product revenues of $227.3 million, representing a 49% increase over 2024 full-year net product revenues Expect significant Vafseo® (vadadustat) revenue growth in 2026 through expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates Pipeline advancement continues with enrollment underway for praliciguat Phase 2 clinical trial in focal segmental glomerulosclerosis (FSGS) and AKB-097 Phase 2 rare kidney disease basket trial planned to begin in 2H 2026 Akebia to Host Conference Call at 8:00 a.m. EST on February 26, 2026 CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Ake

    2/26/26 7:00:00 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NYSE Content Update: Two MSCI Indexes to Begin Trading on NYSE Arca Options

    NYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, Feb. 25, 2026 /CNW/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.  Ashley Mastronardi delivers the pre-market update on February 25thEquities are higher Wednesday morning as Nvidia prepares to release its fourth quarter earnings after market close.MSCI Emerging Markets Index Options and MSCI EAFE Index Options are set to begin trading on NYSE Arca Options today under the ticker symbols MXEF and MXEADynatrace (NYSE:DT) CEO Rick McConnell will

    2/25/26 8:55:00 AM ET
    $BMY
    $DT
    $ICE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology

    $ABBV
    $AKBA
    $AVDL
    $BMY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Encompass Health Corporation

    SC 13G/A - Encompass Health Corp (0000785161) (Subject)

    11/14/24 10:54:00 AM ET
    $EHC
    Hospital/Nursing Management
    Health Care

    Amendment: SEC Form SC 13G/A filed by Avadel Pharmaceuticals plc

    SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)

    11/14/24 6:10:30 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Avadel Pharmaceuticals plc

    SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)

    11/13/24 5:58:54 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care